Locus Cell
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Locus Cell - overview
Established
2020
Location
New Taipei, -, Taiwan - China
Primary Industry
Biotechnology
About
Based in New Taipei City, China, and founded in 2020, Locus Cell operates as a biochemical technology R&D company that focuses on providing cellular gene therapy. The company has cooperated with HITACHI and Minaris. Its cell factory passed the PIC/S GMP standard. The president of the company, Hongneng He, is the general counselor of Taipei Medical University In May 2021, Locus Cell raised TWD 279 million in strategic investment.
Locus Cell has built a cellular factory in compliance with PIC/S GMP, focusing on CDMO services for cellular products. The company also introduced cell therapy products and technology resources, and together with Taiwan's medical clinical resources, created a cell therapy factory.
Current Investors
National Development Fund of the Executive Yuan
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.locus-cell.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.